Niu C, Kefang S, Jing Z, et al
What they found (summary): Development of Melanotan II as a cutaneous drug failed due to the combination of side effects Bifurcation into more selective derivatives was both scientifically and commercially successful PT-141 Bremelanotide (Vyleesi, 2019) Melanotan I Afamelanotide (Scenesse, 2014) Underground use of Melanotan II is safety-problematic Why it matters: This is the definitive historical review by the founders of the field
We cant recommend or direct you to those sources, but we can help you understand the risks and explore safer, legal alternatives
Benign conditions like Laugier-Hunziker Syndrome, however, do not typically "go away." Foster and Murray (2026) describe a condition with a benign but persistent course
You will learn exactly what causes the color, what range of shades is normal, what warning signs demand immediate attention, and how storage conditions change what you see in the vial
Curr Ther Res 1980;27(2):208-216